pharma · Achondroplasia · Amyloid Cardiomyopathy, Transthyretin-Related · BBOT
BridgeBio Oncology Therapeutics is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker BBOT. Primary therapeutic focus areas include Achondroplasia, Amyloid Cardiomyopathy, Tra
Phase 3 · small molecule · Achondroplasia
Infigratinib 0.25 mg/kg/day (QBGJ398-303) is a small-molecule fibroblast growth factor receptor (FGFR) inhibitor developed by BridgeBio Oncology Therapeutics for achondroplasia, a genetic disorder of bone growth. The drug is formulated under the brand name FEBSELTIQ and operates by inhibiting FGFR signaling, which is d
Internal code QBGJ398-303
Infigratinib 0.25 mg/kg/day (QBGJ398-303) is a small-molecule fibroblast growth factor receptor (FGFR) inhibitor developed by BridgeBio Oncology Therapeutics for achondroplasia, a genetic disorder of bone growth. The drug is formulated under the brand name FEBSELTIQ and operates by inhibiting FGFR signaling, which is dysregulated in achondroplasia pathogenesis. The program has completed Phase 3 clinical development, with the latest milestone recorded on 17 March 2026. FEBSELTIQ received European regulatory attention but the marketing application was withdrawn; current regulatory status in other jurisdictions remains not yet disclosed. BridgeBio's strategy centers on addressing the significant unmet medical need in achondroplasia, where growth-limiting complications and functional impairment affect patients throughout life. The Phase 3 completion represents a critical inflection point for the program, though specific efficacy and safety data from the trial have not been disclosed in the available facts. Future regulatory submissions and approval decisions will determine commercial viability and market access across geographies.
Achondroplasia is the most common form of skeletal dysplasia, affecting approximately 1 in 25,000 live births globally. Patients experience progressive growth restriction, spinal complications, and functional impairment that significantly impact quality of life and require ongoing medical management. The condition has historically lacked disease-modifying pharmacological treatments, creating substantial unmet medical need. FEBSELTIQ represents one of the first FGFR-targeted approaches to address the underlying pathophysiology rather than manage symptoms alone, positioning it as potentially transformative for the achondroplasia treatment landscape. The commercial opportunity is defined by a well-characterized patient population, high disease burden, and limited therapeutic alternatives. However, the withdrawn European application signals potential regulatory or commercial challenges that may affect market penetration. Success in achondroplasia could establish a precedent for FGFR inhibition in other skeletal dysplasias and genetic growth disorders, expanding the addressable market. The competitive void in disease-modifying therapies underscores the strategic importance of this program, though regulatory approval timelines and real-world efficacy data remain critical determinants of market success and adoption rates among physicians and patients.
Drug Class: Fibroblast growth factor receptor (FGFR) inhibitor; small-molecule kinase inhibitor.
Mechanism of Action: Inhibition of fibroblast growth factor receptor signaling, which is constitutively activated in achondroplasia due to gain-of-function mutations in FGFR3.
Modality: Small-molecule oral or systemic therapeutic (route of administration not yet disclosed).
Target: Fibroblast growth factor receptor (FGFR).
Brand Name: FEBSELTIQ.
Therapeutic Classification: Antineoplastic and immunomodulating agents (ATC L01), though primary indication is genetic/metabolic disorder rather than oncology.
Related Therapies: Other FGFR inhibitors in development or approved for oncologic indications; symptomatic management approaches for achondroplasia complications (orthopedic, neurosurgical interventions).
Regulatory History: European marketing application withdrawn; approval status in United States, Japan, and China not yet disclosed.
Also known as: ACH, achondroplastic dwarfism
Prevalence: Prevalence at birth: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Achondroplasia is the most common form of chondrodysplasia, characterized by rhizomelia, exaggerated lumbar lordosis, brachydactyly, and macrocephaly with frontal bossing and midface hypoplasia.
ClinicalTrials.gov lists 46 registered studies for Achondroplasia (AACT aggregate).
Phase breakdown: NA (19), PHASE2 (16), PHASE3 (4), PHASE2/PHASE3 (3), PHASE1 (2), PHASE1/PHASE2 (1), PHASE4 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0007037), Orphanet — achondroplasia, NCT00001536, NCT01435629, NCT01516229, NCT01541306, NCT01590446, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 3 initiation
QBGJ398-303 Phase 3 trial (NCT06164951) initiated for infigratinib in achondroplasia.
Phase 3 completed
Phase 3 trial QBGJ398-303 completed; specific results and next regulatory steps not yet disclosed.
The competitive landscape for achondroplasia treatment is notably sparse in disease-modifying pharmacotherapy. The listed competitors (GLIADEL, TEKINEX, ALUNBRIG, KYPROLIS, EVOLTRA, APX-CELECOXIB, INLYTA, MEKTOVI, CABAZITAXEL ACCORD, CABOMETYX, CAPECITABINE SANDOZ, UNITUXIN) represent approved oncologic and non-oncologic agents with distinct mechanisms (glutathione reductase inhibition, protein synthesis inhibition, ALK inhibition, proteasome inhibition, DNA polymerase inhibition, COX-2 inhibition, VEGFR inhibition, MEK inhibition, tubulin inhibition, MET inhibition, thymidylate synthase inhibition, GD2 binding) but do not appear to be direct competitors in achondroplasia treatment. This absence of listed achondroplasia-specific competitors underscores the therapeutic void that FEBSELTIQ aims to address. The withdrawn European application for FEBSELTIQ suggests potential regulatory or commercial headwinds that may have influenced competitive positioning or market strategy. Future approval and market entry will depend on demonstrating superior efficacy and safety versus standard-of-care symptomatic management and any emerging alternative FGFR-targeted or alternative-mechanism therapies in development for achondroplasia.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| GLIADEL | Eisai Co., | Glutathione reductase inhibitor | approved |
| TEKINEX | Teva Pharma GmbH | Protein synthesis inhibitor | approved |
| ALUNBRIG | Lacuna Pharma Pty Ltd | ALK tyrosine kinase receptor inhibitor | approved |
| KYPROLIS | Amgen | 26S proteosome inhibitor | approved |
| EVOLTRA | Amneal Pharma Europe Ltd | DNA polymerase (alpha/delta/epsilon) inhibitor | approved |
| APX-CELECOXIB | Viatris Pharmaceuticals Co., | Cyclooxygenase-2 inhibitor | approved |
| INLYTA | Pfizer Australia Pty Ltd | Vascular endothelial growth factor receptor inhibitor | approved |
| MEKTOVI | Pierre Fabre Australia Pty Ltd | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor | approved |
| CABAZITAXEL ACCORD | Lacuna Pharma Pty Ltd | Tubulin inhibitor | approved |
| CABOMETYX | Ipsen | Hepatocyte growth factor receptor inhibitor | approved |
| CAPECITABINE SANDOZ | Alphapharm Pty Ltd | Thymidylate synthase inhibitor | approved |
| UNITUXIN | United Therapeutics Europe Ltd | Disialoganglioside GD2 binding agent | approved |
| VOSORITIDE | — | Atrial natriuretic peptide receptor B binding agent | Approved |
| INFIGRATINIB | — | Fibroblast growth factor receptor inhibitor | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
European Union: FEBSELTIQ (infigratinib) received a European marketing authorization application (EMEA/H/C/005361) under Marketing Authorization Holder Helsinn Birex Pharmaceuticals Ltd. The application was subsequently withdrawn; no authorization date is recorded. Current status of resubmission or alternative regulatory pathways in the EU is not yet disclosed.
United States (FDA): Regulatory status and approval timeline not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
The withdrawn European application represents a significant regulatory setback and warrants monitoring for disclosed reasons (efficacy, safety, commercial, or procedural factors). Regulatory strategy in other major markets and any resubmission plans remain to be announced.
FEBSELTIQ is a fibroblast growth factor receptor (FGFR) inhibitor in development for achondroplasia, a genetic disorder of bone growth. It is designed to address the underlying pathophysiology by inhibiting dysregulated FGFR signaling.
FEBSELTIQ is not approved in the European Union; the marketing application was withdrawn. Regulatory status in the United States, Japan, and China is not yet disclosed. Phase 3 development is complete as of March 2026.
Infigratinib inhibits fibroblast growth factor receptor (FGFR) signaling. In achondroplasia, FGFR3 is constitutively activated due to gain-of-function mutations, leading to growth restriction. FGFR inhibition aims to normalize signaling and improve growth outcomes.
FEBSELTIQ is developed by BridgeBio Oncology Therapeutics. In the European Union, Helsinn Birex Pharmaceuticals Ltd was listed as the Marketing Authorization Holder for the withdrawn application.
The primary trial is QBGJ398-303 (NCT06164951), a Phase 3 study that completed on 17 March 2026. Detailed trial design, results, and endpoints have not been disclosed.
Infigratinib is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling, which is dysregulated in achondroplasia due to activating mutations in FGFR3.
The indication is achondroplasia, the most common form of skeletal dysplasia, affecting approximately 1 in 25,000 live births. It is characterized by progressive growth restriction and functional impairment.
The Phase 3 trial (QBGJ398-303) evaluated infigratinib at 0.25 mg/kg/day. Route of administration and dosing schedule details are not yet disclosed.
The specific reasons for the European application withdrawal have not been disclosed. Possible factors include regulatory, safety, efficacy, or commercial considerations.
Infigratinib is classified as an antineoplastic and immunomodulating agent (ATC L01), though its primary indication is a genetic metabolic disorder rather than oncology.
Achondroplasia historically lacked disease-modifying pharmacological treatments. Patients experience progressive growth restriction, spinal complications, and functional impairment managed primarily through symptomatic and surgical approaches.
No approved disease-modifying pharmacological competitors for achondroplasia are listed. FEBSELTIQ represents one of the first FGFR-targeted approaches to address underlying pathophysiology in this indication.
Infigratinib has completed Phase 3 clinical development (QBGJ398-303) as of 17 March 2026. Regulatory status and next steps in major markets are not yet disclosed.
BridgeBio Oncology Therapeutics is the sponsor. No partner or co-development arrangement is disclosed.
Infigratinib is a small-molecule fibroblast growth factor receptor inhibitor. Route of administration is not yet disclosed.
The target is fibroblast growth factor receptor (FGFR), specifically FGFR3, which is dysregulated in achondroplasia.
Expected next milestones are not yet disclosed. Key catalysts likely include FDA regulatory decision, disclosure of Phase 3 results, and regulatory actions in other major markets.
Infigratinib 0.25 mg/kg/day → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: BridgeBio's completion of Phase 3 for FEBSELTIQ in achondroplasia represents a significant milestone in targeting a rare genetic disorder with high unmet medical need. However, the withdrawn European application signals potential regulatory or commercial challenges that may require strategic reassessment. The sponsor must now navigate regulatory pathways in other major markets (FDA, PMDA, NMPA) and address any safety or efficacy concerns that may have prompted the European withdrawal.
Competitive Implications: The absence of approved disease-modifying therapies for achondroplasia creates a competitive vacuum. FEBSELTIQ's success or failure will establish precedent for FGFR inhibition in skeletal dysplasias and may influence development strategies for competing programs. Early market entry and clinical evidence of benefit could establish market dominance, while regulatory delays or safety signals could open opportunities for alternative approaches.
Future Catalysts: Key catalysts include (1) disclosure of Phase 3 efficacy and safety data; (2) FDA regulatory decision and potential breakthrough therapy or orphan drug designation; (3) explanation and resolution of the European application withdrawal; (4) regulatory decisions in Japan and China; (5) real-world evidence and long-term safety data post-approval; (6) label expansion to pediatric or other patient subgroups.
Expected Milestones: Regulatory submissions and approval decisions in the United States and other major markets are anticipated, though specific timelines are not yet disclosed. Commercial launch, if approved, would likely target specialized rare disease and genetic disorder treatment centers.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.